Melanoma Cancer CPG Mini-Module – Treatment options for advanced melanoma

The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.

Elizabeth Buchbinder, MD, of Dana-Farber Cancer Institute presents two case studies of advanced disease. The first case study addresses available options and current recommendations for treating patients with advanced melanoma without BRAF mutations. This a case study includes a panel discussion between Dr. Buchbinder, Tina Hieken, MD, of Mayo Clinic, and April Salama, MD, of the Duke Cancer Institute about first-line therapy for regionally limited disease. The second case study of a patient with extensive stage BRAFV600-mutated melanoma includes a discussion of the current recommendations for treating BRAF-mutated melanoma as well as data comparing combination immune checkpoint inhibitor therapy with targeted triplet therapy and their associated clinical benefits.

Run time: Approximately 13 minutes

Target Audience
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants, and radiologists. 

SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described
in this educational activity. 

The Mini Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 09/07/2023). 

The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.